Core Viewpoint - The company, Haixi New Drug (02637.HK), announced a global offering of 11,500,000 H-shares at a price of HKD 86.40 per share, with net proceeds amounting to HKD 940 million [1] Summary by Sections - Global Offering Details - The global offering consists of 11,500,000 H-shares priced at HKD 86.40 each, resulting in net proceeds of HKD 940 million [1] - The Hong Kong public offering accounts for 10% of the total shares, with a subscription rate of 3,165.1 times [1] - The international offering represents 90% of the total shares, with a subscription rate of 6.3 times [1] - Trading Information - If the global offering becomes unconditional on October 20, 2025, trading of the H-shares is expected to commence at 9:00 AM on the same day [1] - H-shares will be traded in board lots of 50 shares, with the stock code being 2637 [1]
海西新药(02637.HK)香港IPO发行价定为每股86.40港元 净筹9.4亿港元